Tioma nabs $86 mln Series A
St. Louis, Missouri and Brisbane, California-based Tioma Therapeutics Inc, which develops anti-CD47 antibodies that treat solid and hematologic cancers, has secured $86 million in Series A financing. RiverVest Venture Partners, Novo Ventures, Roche Venture Fund and GlaxoSmithKline's corporate venture capital arm S.R. One Limited led the round. In addition to the financing, Dr. John McKearn of RiverVest Venture Partners, Dr. Peter Moldt of Novo Ventures, Carole Nuechterlein of Roche Venture Fund and Jill Carroll of S.R. One have been appointed to Tioma's board of directors, with McKearn serving as chair.
16 August 2016•1 min read
